Equities

NANO MRNA Co Ltd

NANO MRNA Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)179.00
  • Today's Change2.00 / 1.13%
  • Shares traded147.30k
  • 1 Year change-13.11%
  • Beta0.9419
Data delayed at least 20 minutes, as of Jul 03 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.

  • Revenue in JPY (TTM)135.51m
  • Net income in JPY-780.00m
  • Incorporated1996
  • Employees18.00
  • Location
    NANO MRNA Co LtdOhnoya Kyobashi Bldg., 1-4-10, KyobashiMINATO-KU 105-6226JapanJPN
  • Phone+81 364324791
  • Fax+81 364324794
  • Websitehttps://www.nanomrna.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kringle Pharma Inc77.93m-904.81m6.41bn13.00--2.64--82.30-159.92-159.9213.58356.640.027--2.805,994,308.00-31.29-19.00-33.20-20.23-----1,161.12-156.5112.85--0.00---82.33---157.41------
Veritas In Silico Inc-100.00bn-100.00bn6.59bn15.00--2.79----------363.52------------------------40.94--0.00--101.54--123.38------
Carna Biosciences, Inc.1.58bn-1.03bn7.08bn67.00--1.91--4.48-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
Chiome Bioscience Inc642.70m-1.30bn7.61bn51.00--6.03--11.84-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
Tsubota Laboratory Inc673.53m-641.32m9.85bn7.00--7.20--14.62-25.15-25.1526.4253.450.27112.0437.7496,218,860.00-25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Noile-Immune Biotech Inc311.30m-975.80m9.87bn28.00--1.85--31.71-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
TMS Co Ltd0.00-960.04m9.87bn14.00--2.86-----25.89-25.890.0085.770.00----0.00-26.14---26.78-------------2,219.420.00-------11.51------
OncoTherapy Science, Inc.610.12m-1.29bn10.02bn54.00--24.00--16.42-6.09-6.092.871.620.5139.087.6911,298,480.00-108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
AnGes Inc249.94m-6.35bn10.44bn145.00--0.3536--41.79-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
Linical Co Ltd12.31bn338.27m11.03bn662.0029.781.2212.880.896514.9814.98544.92364.600.6837--3.5918,591,950.001.884.013.156.3330.7030.992.755.48----0.267250.81-1.671.70-66.32-9.86-10.184.56
Medinet Co Ltd711.82m-1.40bn11.29bn98.00--2.02--15.85-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
3-D Matrix Ltd4.59bn-255.51m11.56bn108.00--31.20--2.52-3.56-3.5662.614.330.78360.51345.16---4.36-42.10-5.76-55.6067.2653.95-5.57-96.031.91--0.922--98.3069.4189.55---30.34--
Nano Mrna Co Ltd135.51m-780.00m12.46bn18.00--3.64--91.95-11.10-11.101.9348.610.02559.029.667,528,222.00-14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
Healios KK124.00m-5.52bn15.68bn64.00--4.24--126.47-72.60-72.601.7041.050.0078--0.37131,937,500.00-34.77-23.55-52.02-28.5281.45---4,440.32-6,580.16---1.900.6824--34.44--26.04---22.00--
Chordia Therapeutics Inc-100.00bn-100.00bn16.32bn21.00--4.41----------56.42----------------------------0.00------112.55------
Data as of Jul 03 2024. Currency figures normalised to NANO MRNA Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.44%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 06 Jun 2024645.20k0.92%
Simplex Asset Management Co., Ltd.as of 06 Jun 2024368.60k0.52%
Data from 31 Mar 2024 - 25 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.